Prabhat Singh Malik

High Impact

Associate Professor

University of Arkansas for Medical Sciences

faculty

22 h-index 226 pubs 1,835 cited

Research Areas

Lung Cancer Diagnosis and Treatment Cancer Treatment and Pharmacology COVID-19 epidemiological studies Cancer-related molecular mechanisms research Health disparities and outcomes MicroRNA in disease regulation Cardiovascular Function and Risk Factors Pharmaceutical Practices and Patient Outcomes

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Prabhat Singh Malik's research focuses on cancer treatment and pharmacology, with a particular emphasis on lung cancer and ovarian cancer. His work has investigated various therapeutic strategies, including neoadjuvant Osimertinib for resectable EGFR-mutated non-small cell lung cancer and Pazopanib-based oral metronomic therapy for platinum-resistant epithelial ovarian cancer. Malik has also explored the role of specific microRNAs (miR-375-3p, miR-197-3p, and miR-15a-5p) as potential biomarkers in lung cancer. His research extends to understanding the impact of comorbidities, such as diabetes and hypertension, on the severity and mortality of infections like COVID-19, drawing on data from India. He has also contributed to the development of national cancer databases aimed at assessing cost and quality of life.

Malik's scholarly contributions are reflected in his publication record and metrics, with a total of 226 publications and an h-index of 22. He is recognized as a highly cited researcher. His work involves clinical trials, observational studies, and the development of research protocols, demonstrating a commitment to advancing medical knowledge and patient outcomes. He is an Associate Professor at the University of Arkansas for Medical Sciences.

Metrics

h-index: 22
Publications: 226
Citations: 1,835

Selected Publications

Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer—A Narrative Review (2025) DOI
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer (2025) DOI
Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic Profiles (2025) DOI
Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells: Lesson from acute graft-versus-host-disease model (2024) DOI
Integrating Artificial Intelligence-Driven Wearable Technology in Oncology Decision-Making: A Narrative Review (2024) DOI
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients (2024) DOI
Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer (2024) DOI
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial (2024) DOI
Retrospective application of WHO reporting system for lung cytopathology with assessment of risk of malignancy (2024) DOI
SMART-ESAS: Smartphone Monitoring and Assessment in Real Time of Edmonton Symptom Assessment System Scores for Patients With Cancer (2024) DOI
Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase ( ALK ) and Ros Proto-oncogene 1 ( ROS1 ) Gene Rearrangements in Non–Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls (2023) DOI
Identification of molecular biomarkers associated with non-small-cell lung carcinoma (NSCLC) using whole-exome sequencing (2023) DOI
Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution (2023) DOI
A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG) (2023) DOI
RNA profile of immuno‐magnetically enriched lung cancer associated exosomes isolated from clinical samples (2023) DOI